מכפיל מחיר להכנסות עתידי Ensysce Biosciences Inc. (ENSC)

Ensysce Biosciences (ENSC) is mitigating ESG risks through the development of abuse-deterrent medications and bioethical compliance. The company's expected P/S ratio demonstrates a fundamental trend where the value of 1.70 aligns with the current metric. High scalability potential is driven by global revenue from proprietary formulas. A unique gastrointestinal drug activation mechanism effectively protects the business from competitors' pricing pressure.

To assess the value of the innovative TAAP and MPAR platforms from Ensysce Biosciences (ENSC), utilize the expected P/S dynamics, which currently stands at 1.70. This indicator compares market capitalization with projected annual revenue, allowing investors to evaluate the sensitivity of share prices to potential cash gaps and the company's debt load prior to the publication of official financial statements.